Kodiak Sciences Ramps Up for Zenkuda BLA Submission After GLOW2 Phase 3 Success and Robust Pipeline Progress
Market Chameleon (Wed, 1-Apr 9:47 AM)
KOD Highlights GLOW2 Phase 3 Success: Zenkuda Shows 62.5% DRSS Improvement and 85% Risk Reduction in Diabetic Retinopathy
Market Chameleon (Fri, 27-Mar 10:30 AM)
Phase 3 Results Position Zenkuda as a Standout in Diabetic Retinopathy—85% Risk Reduction for Sight-Threatening Complications
Market Chameleon (Thu, 26-Mar 9:53 AM)
Kodiak’s Zenkuda Phase 3 Trial Achieves 62.5% Improvement Rate in Diabetic Retinopathy—Durable Benefits and Strong Safety Highlighted
Market Chameleon (Thu, 26-Mar 7:05 AM)
